- Published on
Infectious Disease and Microbiology: Granuloma Inguinale (Donovanosis)
Granuloma inguinale, also known as donovanosis, is a chronic sexually transmitted infection characterized by progressive ulcerative lesions of the genital and perineal regions. It may present as a single lesion or multiple nodules that gradually enlarge and ulcerate. The disease is caused by Klebsiella granulomatis, a Gram-negative intracellular organism that is difficult to culture in laboratory settings.
Epidemiologically, granuloma inguinale is endemic in tropical and developing regions such as India, Papua New Guinea, central Australia, and southern Africa, while it remains rare in developed countries, including the United States. The primary risk factor is geographic exposure through residence, work, or travel in endemic areas. Transmission occurs via sexual contact, and preventive measures mainly involve the use of barrier contraceptives.
Following an incubation period of approximately 2–3 weeks, patients typically develop painless nodules on the genitalia that progressively enlarge and ulcerate. These ulcers are classically described as beefy-red, highly vascular, and prone to bleeding on contact. Unlike many other sexually transmitted infections, regional lymphadenopathy is usually absent. However, subcutaneous spread of infection may result in pseudobuboes. In some cases, verrucous lesions may develop in the perianal area, and advanced disease can lead to scarring and deformities.
Diagnosis is primarily clinical, supported by identification of characteristic “Donovan bodies,” which are intracellular organisms seen in tissue smears or biopsy specimens. The organism is notoriously difficult to culture, and widely available PCR testing is lacking. It is also important to assess for coexisting sexually transmitted infections, as coinfection is common. Differential diagnosis includes infections such as genital herpes, syphilis, chancroid, and lymphogranuloma venereum, as well as noninfectious conditions like malignancy and inflammatory dermatoses.
Treatment requires prolonged antibiotic therapy. First-line treatment consists of Doxycycline administered orally for at least three weeks and continued until complete healing of lesions. Alternative options include azithromycin, ciprofloxacin, erythromycin, and trimethoprim–sulfamethoxazole. In cases with poor response or in immunocompromised patients, an aminoglycoside such as gentamicin may be added. Special considerations are necessary in pregnancy, where erythromycin is preferred due to contraindications of certain antibiotics.
Follow-up is essential to ensure complete resolution, as healing typically occurs from the margins inward and relapses may occur months after treatment. Sexual contacts within the preceding 60 days should be evaluated and managed appropriately. Although prognosis is generally favorable with treatment, complications can include genital pseudoelephantiasis, significant tissue destruction, and, rarely, deep infections such as psoas abscess.
- Published on
Infectious Disease and Microbiology: Gingivitis
Gingivitis is an inflammation of the gingiva that commonly presents with localized bleeding, especially during brushing, and may progress to more serious periodontal disease if untreated. It can be classified into dental plaque–induced and non–plaque-induced types, with plaque-induced gingivitis being the most frequent form. In severe cases, it may lead to systemic symptoms such as fever or even tooth loss secondary to progression into periodontitis.
Epidemiologically, gingivitis is highly prevalent, particularly among adults over 35 years of age. Its incidence is increased in individuals with immunodeficiency and during pregnancy. Several risk factors contribute to its development, including poor dental hygiene, systemic diseases such as diabetes mellitus and coronary artery disease, malocclusion, malnutrition, and infections like HIV. Certain medications, including oral contraceptive pills and Phenytoin, are also associated with an increased risk.
The pathophysiology involves both acute and chronic inflammation of the gingiva due to accumulation of bacterial plaque at the gingival margin. This leads to hyperemia, infiltration of neutrophils, and bacterial proliferation. The most common causative organisms include Streptococcus species, actinomycetes, spirochetes, and various anaerobic bacteria. Persistent inflammation can eventually damage the supporting structures of the teeth.
Clinically, gingivitis often begins with bleeding gums during brushing, which is usually the earliest symptom. Patients may also report halitosis. On physical examination, the gingiva appears erythematous, edematous, and may bleed easily, with visible plaque and calculus. In advanced cases, the tissue may become necrotic, and a severe form known as Vincent’s angina may develop, characterized by pain, swelling, fever, and lymphadenopathy.
Diagnosis of gingivitis is primarily clinical, based on history and physical findings. Laboratory investigations are generally not required. It is important to differentiate gingivitis from other oral conditions such as periodontitis, glossitis, and pericoronitis. Close follow-up with a dental provider is essential to monitor progression and ensure adequate management.
Treatment focuses on removal of dental plaque and improvement of oral hygiene. Professional debridement and use of antimicrobial mouth rinses such as chlorhexidine are first-line measures. In severe cases, antibiotics targeting oral flora, including Metronidazole, penicillins, or clindamycin, may be required. Additional measures include elimination of local irritants, smoking cessation, and regular dental checkups.
The prognosis of gingivitis is excellent with appropriate treatment and adherence to good oral hygiene practices. However, recurrence is common if preventive measures are not maintained. Potential complications include progression to severe periodontal disease, tooth loss, gingival or bone abscess formation, and possible associations with systemic conditions such as coronary artery disease.
- Published on
Infectious Disease and Microbiology: Giardiasis
Giardiasis is a parasitic infection of the upper small intestine caused by Giardia lamblia (also known as Giardia intestinalis). It is one of the most common causes of protozoal diarrhea worldwide and is transmitted primarily via the fecal–oral route. Infection occurs through ingestion of cysts in contaminated water, food, or through direct person-to-person contact. Although many infections are asymptomatic, symptomatic cases can lead to prolonged gastrointestinal illness.
Epidemiologically, giardiasis has a global distribution and is especially common in areas with poor sanitation. It is responsible for thousands of cases annually, including approximately 20,000 cases per year in the United States. Outbreaks are often linked to contaminated water supplies, while sporadic cases commonly occur through direct transmission in settings such as daycare centers, institutions, and among individuals with close contact. Travelers to endemic regions, particularly in parts of Asia, are at increased risk.
The pathophysiology begins with ingestion of infective cysts, which are resistant and can survive in water for extended periods. Once ingested, the cysts undergo excystation in the upper gastrointestinal tract, releasing trophozoites that attach to the mucosa of the duodenum and jejunum. These organisms disrupt the intestinal brush border, leading to malabsorption and diarrhea. The infection does not typically invade tissues but causes functional impairment of absorption.
Clinically, giardiasis may be asymptomatic or present after an incubation period of about 1–3 weeks. The hallmark symptom is diarrhea, which is often subacute and may persist for weeks or months if untreated. Stools are typically pale, bulky, foul-smelling, and greasy due to fat malabsorption (steatorrhea). Other symptoms include abdominal cramps, bloating, excessive gas, weight loss, anorexia, and occasionally nausea or vomiting. Blood and mucus are usually absent, and systemic symptoms are mild. Chronic infection may occur, especially in immunocompromised individuals.
Diagnosis is primarily made by identifying cysts or trophozoites in stool samples through microscopy. Multiple stool examinations increase diagnostic yield. Antigen detection tests using ELISA or immunofluorescence are highly sensitive and specific and are commonly used. In rare or difficult cases, duodenal sampling may be required. Histological examination may show villous atrophy and mild inflammation.
Treatment is indicated for symptomatic patients and to prevent transmission in asymptomatic carriers, particularly children. First-line therapy includes Metronidazole, Tinidazole, or Nitazoxanide, all of which are highly effective. Alternative treatments include albendazole or quinacrine in resistant cases. Patients should avoid alcohol while taking metronidazole due to adverse reactions. Persistent or recurrent infection may require retreatment or evaluation of close contacts.
The prognosis of giardiasis is generally good, with most cases resolving either spontaneously or with treatment. However, untreated infection may lead to chronic diarrhea, malabsorption, steatorrhea, and weight loss. Complications can include lactose intolerance and nutritional deficiencies. Preventive measures such as proper sanitation, boiling or filtering drinking water, and good personal hygiene are essential in reducing transmission.
- Published on
Infectious Disease and Microbiology: Genital Herpes
Genital herpes is a common sexually transmitted infection caused by the Herpes Simplex Virus, characterized by painful vesicular lesions on the genitalia. It is most frequently caused by HSV-2, although HSV-1 is increasingly responsible for genital infections. The disease is marked by recurrent episodes due to the virus’s ability to establish lifelong latency in sensory nerve ganglia, with periodic reactivation leading to symptomatic or asymptomatic viral shedding.
Epidemiologically, genital herpes is highly prevalent, with tens of millions of individuals affected worldwide. In the United States alone, at least 50 million people are infected. HSV-2 seroprevalence has slightly declined over time, while genital HSV-1 infections appear to be increasing. Higher prevalence is observed among individuals of lower socioeconomic status and certain populations, reflecting differences in sexual networks. Women are at greater risk of acquiring HSV-2 infection compared to men.
Transmission occurs primarily through sexual contact with an infected individual, including during asymptomatic viral shedding, which is more common in HSV-2 infection. Risk factors include unprotected sexual intercourse and having multiple sexual partners. Preventive strategies include consistent condom use, abstinence during active lesions or prodromal symptoms, and suppressive antiviral therapy in individuals with frequent recurrences. Suppressive treatment with antiviral agents such as Valacyclovir has been shown to reduce transmission risk.
The clinical presentation varies between primary and recurrent infections. The incubation period is typically 2–7 days. Primary infection is usually more severe and may last up to three weeks, presenting with painful vesicles that rupture into ulcers, along with systemic symptoms such as fever, headache, malaise, and myalgias. Recurrent episodes are generally milder and shorter in duration and are often preceded by prodromal symptoms such as tingling, burning, or pain at the site of recurrence. Over time, the frequency and severity of recurrences tend to decrease.
On physical examination, patients typically have multiple small vesicles on an erythematous base that progress to painful ulcers. In women, lesions commonly involve the vulva, vaginal vestibule, and cervix, while in men, lesions are found on the penis, scrotum, or surrounding areas. Tender regional lymphadenopathy is common. Complications such as urethritis, cervicitis, or proctitis may occur depending on the site of infection.
Diagnosis is confirmed through laboratory testing, as clinical diagnosis alone may be inaccurate. Polymerase chain reaction (PCR) testing for HSV DNA is the most sensitive method and can distinguish between HSV-1 and HSV-2. Viral culture and serologic testing for HSV antibodies may also be used, although culture has lower sensitivity, especially in recurrent lesions.
Management involves antiviral therapy to reduce symptom severity and duration. First-line treatments include Acyclovir, Valacyclovir, and Famciclovir. For primary infection, treatment is typically given for 7–10 days, while recurrent episodes may be treated episodically or with long-term suppressive therapy in patients with frequent recurrences. Severe or disseminated infections may require intravenous antiviral therapy.
The prognosis is generally good in immunocompetent individuals, although the infection is lifelong with potential for recurrence. Complications include secondary infections, aseptic meningitis, and increased susceptibility to HIV transmission. Neonatal herpes, acquired during childbirth, is a serious condition with high mortality if untreated. Patient education is essential and should emphasize the chronic nature of the disease, risk of transmission even without symptoms, and the importance of preventive measures.
Genital herpes is a common sexually transmitted infection caused by the Herpes Simplex Virus, characterized by painful vesicular lesions on the genitalia. It is most frequently caused by HSV-2, although HSV-1 is increasingly responsible for genital infections. The disease is marked by recurrent episodes due to the virus’s ability to establish lifelong latency in sensory nerve ganglia, with periodic reactivation leading to symptomatic or asymptomatic viral shedding.
Epidemiologically, genital herpes is highly prevalent, with tens of millions of individuals affected worldwide. In the United States alone, at least 50 million people are infected. HSV-2 seroprevalence has slightly declined over time, while genital HSV-1 infections appear to be increasing. Higher prevalence is observed among individuals of lower socioeconomic status and certain populations, reflecting differences in sexual networks. Women are at greater risk of acquiring HSV-2 infection compared to men.
Transmission occurs primarily through sexual contact with an infected individual, including during asymptomatic viral shedding, which is more common in HSV-2 infection. Risk factors include unprotected sexual intercourse and having multiple sexual partners. Preventive strategies include consistent condom use, abstinence during active lesions or prodromal symptoms, and suppressive antiviral therapy in individuals with frequent recurrences. Suppressive treatment with antiviral agents such as Valacyclovir has been shown to reduce transmission risk.
The clinical presentation varies between primary and recurrent infections. The incubation period is typically 2–7 days. Primary infection is usually more severe and may last up to three weeks, presenting with painful vesicles that rupture into ulcers, along with systemic symptoms such as fever, headache, malaise, and myalgias. Recurrent episodes are generally milder and shorter in duration and are often preceded by prodromal symptoms such as tingling, burning, or pain at the site of recurrence. Over time, the frequency and severity of recurrences tend to decrease.
On physical examination, patients typically have multiple small vesicles on an erythematous base that progress to painful ulcers. In women, lesions commonly involve the vulva, vaginal vestibule, and cervix, while in men, lesions are found on the penis, scrotum, or surrounding areas. Tender regional lymphadenopathy is common. Complications such as urethritis, cervicitis, or proctitis may occur depending on the site of infection.
Diagnosis is confirmed through laboratory testing, as clinical diagnosis alone may be inaccurate. Polymerase chain reaction (PCR) testing for HSV DNA is the most sensitive method and can distinguish between HSV-1 and HSV-2. Viral culture and serologic testing for HSV antibodies may also be used, although culture has lower sensitivity, especially in recurrent lesions.
Management involves antiviral therapy to reduce symptom severity and duration. First-line treatments include Acyclovir, Valacyclovir, and Famciclovir. For primary infection, treatment is typically given for 7–10 days, while recurrent episodes may be treated episodically or with long-term suppressive therapy in patients with frequent recurrences. Severe or disseminated infections may require intravenous antiviral therapy.
The prognosis is generally good in immunocompetent individuals, although the infection is lifelong with potential for recurrence. Complications include secondary infections, aseptic meningitis, and increased susceptibility to HIV transmission. Neonatal herpes, acquired during childbirth, is a serious condition with high mortality if untreated. Patient education is essential and should emphasize the chronic nature of the disease, risk of transmission even without symptoms, and the importance of preventive measures.
- Published on
Infectious Disease and Microbiology: Gas Gangrene
Gas gangrene is a severe, life-threatening infection of muscle and soft tissue caused by toxin- and gas-producing bacteria of the genus Clostridium, most commonly Clostridium perfringens. It is characterized by rapidly progressive muscle necrosis, severe pain, gas formation within tissues, and systemic toxicity that can lead to sepsis and death. The disease typically develops within 1–4 days after trauma, although longer incubation periods may occur. Historically, it has been strongly associated with wartime injuries, but it can also arise following minor trauma, surgery, or even spontaneously.
Epidemiologically, trauma accounts for approximately half of all cases, with an estimated 1,000–3,000 cases occurring annually in the United States. The condition is more common in men and typically affects individuals aged 35–40 years. Risk factors include conditions that impair blood supply or immune response, such as diabetes mellitus, peripheral vascular disease, atherosclerosis, chronic alcoholism, malnutrition, HIV/AIDS, corticosteroid use, and intravenous drug use. Open wounds, burns, and surgical procedures also increase susceptibility.
The pathophysiology of gas gangrene is closely related to the anaerobic environment created by compromised blood supply in damaged tissues, which allows clostridial spores to germinate and proliferate. The bacteria produce multiple toxins, most notably alpha-toxin, which has phospholipase activity that destroys cell membranes. This leads to widespread destruction of red blood cells, white blood cells, platelets, and muscle tissue, resulting in necrosis, hemolysis, and shock. Other toxins, such as collagenases, further damage blood vessels and surrounding tissues, facilitating rapid spread of infection.
Clinically, the disease often begins with sudden, severe pain at the site of injury, which is disproportionate to physical findings. Early signs may include swelling and tenderness, followed by skin discoloration that progresses to violaceous changes and the formation of bullae containing foul-smelling discharge. Crepitus due to gas formation may be palpable. Systemic signs range from mild fever and tachycardia to severe septic shock. Hemolysis may cause jaundice and dark urine, while patients may remain conscious despite profound hypotension in early stages.
Diagnosis is primarily clinical but supported by laboratory and imaging findings. Laboratory tests may reveal anemia, hemolysis, electrolyte disturbances, renal dysfunction, and metabolic acidosis. Gram stain of wound exudate typically shows large gram-positive rods. Imaging studies such as X-rays, ultrasound, CT, or MRI can demonstrate gas within soft tissues. Definitive diagnosis may be confirmed by tissue biopsy and culture, with surgical exploration revealing pale, non-contractile necrotic muscle.
Treatment is an emergency and requires immediate, aggressive intervention. The cornerstone of management is prompt surgical debridement of all necrotic tissue, which is the most critical life-saving measure. This is combined with high-dose intravenous antibiotics, typically clindamycin and penicillin. Supportive care includes aggressive fluid resuscitation, management of shock, and correction of metabolic abnormalities. Hyperbaric oxygen therapy may be used as an adjunct, although it should never delay surgery.
The prognosis depends on the speed of diagnosis and treatment. Early intervention significantly reduces mortality, whereas delayed treatment is associated with high rates of complications and death. Outcomes are worse in patients with spontaneous gas gangrene or significant comorbidities. Complications include hemolysis, disseminated intravascular coagulation, acute renal failure, acute respiratory distress syndrome, shock, and death. Survivors may require amputation or experience permanent disability, highlighting the importance of early recognition and urgent management.
- Published on
Infectious Disease And Microbiology – Endocarditis (Prosthetic Valve)
Prosthetic valve endocarditis is an infection involving prosthetic heart valves or associated prosthetic material. It is most commonly caused by bacteria, especially Gram-positive organisms, although fungi and, rarely, organisms such as chlamydiae or rickettsiae may also be responsible. This form of endocarditis is a serious complication of valve replacement and can arise either early after surgery or later through bloodstream spread from another infectious source.
The incidence of prosthetic valve infective endocarditis is approximately 0.3–1% per patient-year. The most important risk factors are healthcare-associated infections, chronic intravascular access, and hemodialysis. Additional predisposing factors include the presence of prosthetic valve material itself and any circumstances that increase the likelihood of bloodstream infection.
Prevention includes antibiotic prophylaxis for high-risk patients, particularly before dental procedures that involve manipulation of gingival tissue or disruption of the oral mucosa. Prophylaxis is also considered reasonable for certain respiratory, skin, soft tissue, or muscle procedures in those at highest risk. Recommended prophylactic regimens include a single dose of amoxicillin 2 g or clindamycin 600 mg administered 30–60 minutes before the procedure. Antibiotic prophylaxis is not recommended for gastrointestinal or genitourinary procedures.
The pathophysiology of prosthetic valve endocarditis involves contamination during implantation, later hematogenous seeding of the prosthesis, or contiguous spread of nearby infection. Staphylococci are the most common causes. Early-onset prosthetic valve endocarditis, occurring within 60 days of surgery, is more often due to hospital-acquired pathogens, whereas late-onset infection is caused by organisms more similar to those seen in native valve endocarditis. Early infections are commonly caused by Staphylococcus aureus, coagulase-negative staphylococci, enterococci, Gram-negative bacilli, fungi, and occasionally streptococci. Late infections are more often caused by S. aureus, coagulase-negative staphylococci, streptococci, enterococci, fungi, and Gram-negative bacilli. Culture-negative cases may occur, most often after recent antibiotic exposure or with fastidious organisms such as Bartonella, Coxiella burnetii, Brucella, or Tropheryma whipplei.
The clinical presentation is highly variable. Some patients present with an acute toxic illness and high fever, whereas others have a more indolent subacute course. In any patient with a prosthetic valve and unexplained fever, endocarditis must be strongly considered. Fever is present in more than 70% of cases, and other symptoms may include weakness, chills, sweats, anorexia, weight loss, nausea, and malaise. A careful history should also explore travel, animal exposure, and consumption of unpasteurized dairy products, which may suggest unusual pathogens.
Diagnosis is commonly based on the modified Duke criteria, which combine clinical, microbiologic, and echocardiographic data. Major criteria include persistently positive blood cultures for typical organisms and evidence of endocardial involvement, such as vegetations, abscesses, prosthetic valve dehiscence, or new valvular regurgitation. Minor criteria include predisposition, fever, vascular phenomena, immunologic phenomena, and microbiologic findings that do not meet major criteria.
On physical examination, patients may have a new or changed murmur or signs of congestive heart failure. Because embolic and metastatic complications are common, a full examination should assess for neurologic deficits, splenic involvement, spinal tenderness, joint infection, or other distant sites of disease.
Initial laboratory workup includes complete blood count, electrolytes, renal and liver function tests, inflammatory markers, urinalysis, and multiple blood cultures. At least three sets of blood cultures should be obtained within the first 24 hours before starting antibiotics. The first two sets are positive in most patients. Leukocytosis and elevated ESR or CRP are common. In culture-negative cases, serologic testing for organisms such as Coxiella burnetii and Bartonella should be considered. Blood cultures should be repeated every 24–48 hours until the infection has cleared.
Transesophageal echocardiography is the imaging test of choice because prosthetic valves often create artifact on transthoracic studies and because prosthetic valve infections frequently involve paravalvular complications. TEE has high sensitivity and specificity for detecting vegetations, abscesses, and dehiscence and should be performed as soon as possible when prosthetic valve endocarditis is suspected. Additional imaging of the brain, lungs, abdomen, or spine may be needed if embolic events, abscesses, or mycotic aneurysms are suspected. Electrocardiography is also important to detect baseline or evolving conduction abnormalities, which may indicate abscess extension.
Treatment requires prolonged bactericidal intravenous antibiotic therapy, with regimens tailored to the causative organism and its susceptibilities. For streptococcal infections, treatment typically includes penicillin G or ceftriaxone plus gentamicin, with vancomycin used in selected allergic patients. For enterococci or highly penicillin-resistant streptococci, ampicillin plus gentamicin is commonly used, or vancomycin plus gentamicin if ampicillin cannot be given. Methicillin-susceptible staphylococcal infections are treated with nafcillin plus rifampin for at least six weeks, with gentamicin added for the first two weeks. Methicillin-resistant staphylococcal infections are treated with vancomycin plus rifampin for at least six weeks, again with gentamicin for two weeks. Rifampin is often delayed by a few days because resistance can develop quickly if started too early.
Management requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiovascular surgery. Patients with prosthetic valve endocarditis should be evaluated early for surgery. Valve replacement may be necessary in cases of prosthetic valve dehiscence, perforation, fistula formation, large abscess, severe structural damage, or failure of medical therapy because of highly resistant organisms.
All patients require hospitalization for monitoring, intravenous therapy, and expedited evaluation. They may be discharged once fevers have resolved for more than 24 hours, vital signs are stable, and a safe plan for continued antibiotic treatment and follow-up is in place. During and after therapy, patients should be monitored closely for relapse, treatment complications, and new cardiac dysfunction. At completion of therapy, transthoracic echocardiography is recommended to establish a new baseline for valve and cardiac function.
Patient education is important and should include the importance of good oral hygiene, prevention of future endocarditis associated with dental procedures, and recognition of symptoms of valvular dysfunction. Prognosis depends on several factors. Higher mortality is associated with healthcare-associated infection, congestive heart failure, older age, S. aureus infection, persistent bacteremia, stroke, and intracardiac abscess. In-hospital mortality is substantial. Complications include periprosthetic leak, ring abscess, congestive heart failure, cerebral emboli, stroke, renal infarction, immune complex glomerulonephritis, mycotic aneurysm, meningitis, cerebritis, splenic infarction or abscess, heart block, and pulmonary embolism in right-sided disease.
Prosthetic valve endocarditis is an infection involving prosthetic heart valves or associated prosthetic material. It is most commonly caused by bacteria, especially Gram-positive organisms, although fungi and, rarely, organisms such as chlamydiae or rickettsiae may also be responsible. This form of endocarditis is a serious complication of valve replacement and can arise either early after surgery or later through bloodstream spread from another infectious source.
The incidence of prosthetic valve infective endocarditis is approximately 0.3–1% per patient-year. The most important risk factors are healthcare-associated infections, chronic intravascular access, and hemodialysis. Additional predisposing factors include the presence of prosthetic valve material itself and any circumstances that increase the likelihood of bloodstream infection.
Prevention includes antibiotic prophylaxis for high-risk patients, particularly before dental procedures that involve manipulation of gingival tissue or disruption of the oral mucosa. Prophylaxis is also considered reasonable for certain respiratory, skin, soft tissue, or muscle procedures in those at highest risk. Recommended prophylactic regimens include a single dose of amoxicillin 2 g or clindamycin 600 mg administered 30–60 minutes before the procedure. Antibiotic prophylaxis is not recommended for gastrointestinal or genitourinary procedures.
The pathophysiology of prosthetic valve endocarditis involves contamination during implantation, later hematogenous seeding of the prosthesis, or contiguous spread of nearby infection. Staphylococci are the most common causes. Early-onset prosthetic valve endocarditis, occurring within 60 days of surgery, is more often due to hospital-acquired pathogens, whereas late-onset infection is caused by organisms more similar to those seen in native valve endocarditis. Early infections are commonly caused by Staphylococcus aureus, coagulase-negative staphylococci, enterococci, Gram-negative bacilli, fungi, and occasionally streptococci. Late infections are more often caused by S. aureus, coagulase-negative staphylococci, streptococci, enterococci, fungi, and Gram-negative bacilli. Culture-negative cases may occur, most often after recent antibiotic exposure or with fastidious organisms such as Bartonella, Coxiella burnetii, Brucella, or Tropheryma whipplei.
The clinical presentation is highly variable. Some patients present with an acute toxic illness and high fever, whereas others have a more indolent subacute course. In any patient with a prosthetic valve and unexplained fever, endocarditis must be strongly considered. Fever is present in more than 70% of cases, and other symptoms may include weakness, chills, sweats, anorexia, weight loss, nausea, and malaise. A careful history should also explore travel, animal exposure, and consumption of unpasteurized dairy products, which may suggest unusual pathogens.
Diagnosis is commonly based on the modified Duke criteria, which combine clinical, microbiologic, and echocardiographic data. Major criteria include persistently positive blood cultures for typical organisms and evidence of endocardial involvement, such as vegetations, abscesses, prosthetic valve dehiscence, or new valvular regurgitation. Minor criteria include predisposition, fever, vascular phenomena, immunologic phenomena, and microbiologic findings that do not meet major criteria.
On physical examination, patients may have a new or changed murmur or signs of congestive heart failure. Because embolic and metastatic complications are common, a full examination should assess for neurologic deficits, splenic involvement, spinal tenderness, joint infection, or other distant sites of disease.
Initial laboratory workup includes complete blood count, electrolytes, renal and liver function tests, inflammatory markers, urinalysis, and multiple blood cultures. At least three sets of blood cultures should be obtained within the first 24 hours before starting antibiotics. The first two sets are positive in most patients. Leukocytosis and elevated ESR or CRP are common. In culture-negative cases, serologic testing for organisms such as Coxiella burnetii and Bartonella should be considered. Blood cultures should be repeated every 24–48 hours until the infection has cleared.
Transesophageal echocardiography is the imaging test of choice because prosthetic valves often create artifact on transthoracic studies and because prosthetic valve infections frequently involve paravalvular complications. TEE has high sensitivity and specificity for detecting vegetations, abscesses, and dehiscence and should be performed as soon as possible when prosthetic valve endocarditis is suspected. Additional imaging of the brain, lungs, abdomen, or spine may be needed if embolic events, abscesses, or mycotic aneurysms are suspected. Electrocardiography is also important to detect baseline or evolving conduction abnormalities, which may indicate abscess extension.
Treatment requires prolonged bactericidal intravenous antibiotic therapy, with regimens tailored to the causative organism and its susceptibilities. For streptococcal infections, treatment typically includes penicillin G or ceftriaxone plus gentamicin, with vancomycin used in selected allergic patients. For enterococci or highly penicillin-resistant streptococci, ampicillin plus gentamicin is commonly used, or vancomycin plus gentamicin if ampicillin cannot be given. Methicillin-susceptible staphylococcal infections are treated with nafcillin plus rifampin for at least six weeks, with gentamicin added for the first two weeks. Methicillin-resistant staphylococcal infections are treated with vancomycin plus rifampin for at least six weeks, again with gentamicin for two weeks. Rifampin is often delayed by a few days because resistance can develop quickly if started too early.
Management requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiovascular surgery. Patients with prosthetic valve endocarditis should be evaluated early for surgery. Valve replacement may be necessary in cases of prosthetic valve dehiscence, perforation, fistula formation, large abscess, severe structural damage, or failure of medical therapy because of highly resistant organisms.
All patients require hospitalization for monitoring, intravenous therapy, and expedited evaluation. They may be discharged once fevers have resolved for more than 24 hours, vital signs are stable, and a safe plan for continued antibiotic treatment and follow-up is in place. During and after therapy, patients should be monitored closely for relapse, treatment complications, and new cardiac dysfunction. At completion of therapy, transthoracic echocardiography is recommended to establish a new baseline for valve and cardiac function.
Patient education is important and should include the importance of good oral hygiene, prevention of future endocarditis associated with dental procedures, and recognition of symptoms of valvular dysfunction. Prognosis depends on several factors. Higher mortality is associated with healthcare-associated infection, congestive heart failure, older age, S. aureus infection, persistent bacteremia, stroke, and intracardiac abscess. In-hospital mortality is substantial. Complications include periprosthetic leak, ring abscess, congestive heart failure, cerebral emboli, stroke, renal infarction, immune complex glomerulonephritis, mycotic aneurysm, meningitis, cerebritis, splenic infarction or abscess, heart block, and pulmonary embolism in right-sided disease.
- Published on
Infectious Disease And Microbiology – Endocarditis (Native Valves)
Endocarditis is an infection of the endocardial surface of the heart, most commonly involving the heart valves. It is typically caused by bacteria, though fungi and, rarely, organisms such as chlamydiae or rickettsiae may be responsible. In native valve infective endocarditis (NVIE), the mitral valve is most frequently affected, followed by the aortic valve. The tricuspid valve is more commonly involved in individuals who use intravenous drugs, while pulmonic valve involvement is rare. In some cases, multiple valves may be infected simultaneously.
The incidence of NVIE ranges from approximately 1.7 to 6.2 cases per 100,000 person-years, but is significantly higher among intravenous drug users. Risk factors include intravenous drug use, prior history of endocarditis, chronic intravascular access, implanted cardiac devices, congenital heart disease, bicuspid aortic valve, rheumatic heart disease, and degenerative valvular disease. Preventive strategies include antibiotic prophylaxis for high-risk individuals—such as those with prosthetic valves, prior endocarditis, certain congenital heart diseases, or cardiac transplant recipients with valvulopathy—especially before dental procedures involving manipulation of the gingiva or oral mucosa.
The most common causative organisms are Gram-positive bacteria, with Staphylococcus aureus now being the leading cause of NVIE. Other important pathogens include viridans group streptococci, Streptococcus bovis, enterococci, coagulase-negative staphylococci, and the HACEK group of organisms. Fungal infections account for a smaller proportion of cases. Approximately 10% of cases are culture-negative, often due to prior antibiotic use or infection with fastidious organisms such as Bartonella or Coxiella burnetii.
Clinically, NVIE presents with a wide range of symptoms resulting from valvular infection, embolic phenomena, metastatic infection, and immune complex deposition. Fever is present in over 90% of patients, along with nonspecific symptoms such as malaise, fatigue, weight loss, and chills. The modified Duke criteria are widely used for diagnosis and incorporate clinical, microbiological, and echocardiographic findings. Major criteria include positive blood cultures with typical organisms and evidence of endocardial involvement on echocardiography, while minor criteria include fever, predisposing conditions, vascular and immunologic phenomena, and less specific microbiologic evidence.
On physical examination, a new or changing heart murmur is found in the majority of patients. Other findings may include petechiae, splinter hemorrhages, Osler nodes, Janeway lesions, and Roth spots, although these are less common. A thorough examination is necessary to detect complications such as embolic events or metastatic infections.
Diagnosis requires prompt laboratory and imaging evaluation. Blood cultures are critical and should be obtained before starting antibiotics, with at least three sets drawn within the first 24 hours. Most cases can be diagnosed based on positive blood cultures. Laboratory findings often include leukocytosis, elevated inflammatory markers, and abnormalities on urinalysis such as hematuria or proteinuria. In cases of culture-negative endocarditis, serologic testing for atypical organisms may be necessary.
Echocardiography is the imaging modality of choice. Transthoracic echocardiography (TTE) is often used initially, but transesophageal echocardiography (TEE) is more sensitive and is preferred when clinical suspicion is high or when TTE results are inconclusive. Imaging may reveal vegetations, abscesses, or valvular dysfunction. Additional imaging studies may be required to evaluate for embolic complications or abscess formation in other organs.
Treatment involves prolonged intravenous bactericidal antibiotic therapy tailored to the causative organism and its antimicrobial susceptibilities. Empiric therapy is initiated based on clinical suspicion and risk factors. Common regimens include penicillin or ceftriaxone for streptococcal infections, ampicillin with gentamicin for enterococci, and nafcillin or vancomycin for Staphylococcus aureus. Therapy typically lasts several weeks to ensure eradication of infection within vegetations.
Surgical intervention is required in approximately 30–50% of cases and is considered in patients with heart failure, uncontrolled infection, large vegetations with recurrent emboli, or complications such as abscess formation. Management often requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiac surgery teams.
Patients with endocarditis require hospitalization for initiation of treatment and close monitoring. Follow-up includes repeated blood cultures to confirm clearance of infection, monitoring for complications, and echocardiography to assess cardiac function after treatment. Patient education is important, particularly regarding oral hygiene and prevention of future infections.
The prognosis of NVIE depends on multiple factors, including the causative organism, patient comorbidities, and presence of complications. Mortality remains significant, with rates approaching 40% at one year. Poor prognostic factors include heart failure, infection with Staphylococcus aureus, older age, immunosuppression, and extension of infection beyond the valve. Complications include heart failure, stroke, systemic emboli, renal infarction, glomerulonephritis, mycotic aneurysms, and metastatic infections such as splenic abscess or meningitis.
Endocarditis is an infection of the endocardial surface of the heart, most commonly involving the heart valves. It is typically caused by bacteria, though fungi and, rarely, organisms such as chlamydiae or rickettsiae may be responsible. In native valve infective endocarditis (NVIE), the mitral valve is most frequently affected, followed by the aortic valve. The tricuspid valve is more commonly involved in individuals who use intravenous drugs, while pulmonic valve involvement is rare. In some cases, multiple valves may be infected simultaneously.
The incidence of NVIE ranges from approximately 1.7 to 6.2 cases per 100,000 person-years, but is significantly higher among intravenous drug users. Risk factors include intravenous drug use, prior history of endocarditis, chronic intravascular access, implanted cardiac devices, congenital heart disease, bicuspid aortic valve, rheumatic heart disease, and degenerative valvular disease. Preventive strategies include antibiotic prophylaxis for high-risk individuals—such as those with prosthetic valves, prior endocarditis, certain congenital heart diseases, or cardiac transplant recipients with valvulopathy—especially before dental procedures involving manipulation of the gingiva or oral mucosa.
The most common causative organisms are Gram-positive bacteria, with Staphylococcus aureus now being the leading cause of NVIE. Other important pathogens include viridans group streptococci, Streptococcus bovis, enterococci, coagulase-negative staphylococci, and the HACEK group of organisms. Fungal infections account for a smaller proportion of cases. Approximately 10% of cases are culture-negative, often due to prior antibiotic use or infection with fastidious organisms such as Bartonella or Coxiella burnetii.
Clinically, NVIE presents with a wide range of symptoms resulting from valvular infection, embolic phenomena, metastatic infection, and immune complex deposition. Fever is present in over 90% of patients, along with nonspecific symptoms such as malaise, fatigue, weight loss, and chills. The modified Duke criteria are widely used for diagnosis and incorporate clinical, microbiological, and echocardiographic findings. Major criteria include positive blood cultures with typical organisms and evidence of endocardial involvement on echocardiography, while minor criteria include fever, predisposing conditions, vascular and immunologic phenomena, and less specific microbiologic evidence.
On physical examination, a new or changing heart murmur is found in the majority of patients. Other findings may include petechiae, splinter hemorrhages, Osler nodes, Janeway lesions, and Roth spots, although these are less common. A thorough examination is necessary to detect complications such as embolic events or metastatic infections.
Diagnosis requires prompt laboratory and imaging evaluation. Blood cultures are critical and should be obtained before starting antibiotics, with at least three sets drawn within the first 24 hours. Most cases can be diagnosed based on positive blood cultures. Laboratory findings often include leukocytosis, elevated inflammatory markers, and abnormalities on urinalysis such as hematuria or proteinuria. In cases of culture-negative endocarditis, serologic testing for atypical organisms may be necessary.
Echocardiography is the imaging modality of choice. Transthoracic echocardiography (TTE) is often used initially, but transesophageal echocardiography (TEE) is more sensitive and is preferred when clinical suspicion is high or when TTE results are inconclusive. Imaging may reveal vegetations, abscesses, or valvular dysfunction. Additional imaging studies may be required to evaluate for embolic complications or abscess formation in other organs.
Treatment involves prolonged intravenous bactericidal antibiotic therapy tailored to the causative organism and its antimicrobial susceptibilities. Empiric therapy is initiated based on clinical suspicion and risk factors. Common regimens include penicillin or ceftriaxone for streptococcal infections, ampicillin with gentamicin for enterococci, and nafcillin or vancomycin for Staphylococcus aureus. Therapy typically lasts several weeks to ensure eradication of infection within vegetations.
Surgical intervention is required in approximately 30–50% of cases and is considered in patients with heart failure, uncontrolled infection, large vegetations with recurrent emboli, or complications such as abscess formation. Management often requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiac surgery teams.
Patients with endocarditis require hospitalization for initiation of treatment and close monitoring. Follow-up includes repeated blood cultures to confirm clearance of infection, monitoring for complications, and echocardiography to assess cardiac function after treatment. Patient education is important, particularly regarding oral hygiene and prevention of future infections.
The prognosis of NVIE depends on multiple factors, including the causative organism, patient comorbidities, and presence of complications. Mortality remains significant, with rates approaching 40% at one year. Poor prognostic factors include heart failure, infection with Staphylococcus aureus, older age, immunosuppression, and extension of infection beyond the valve. Complications include heart failure, stroke, systemic emboli, renal infarction, glomerulonephritis, mycotic aneurysms, and metastatic infections such as splenic abscess or meningitis.
- Published on
Infectious Disease And Microbiology – Encephalitis
Encephalitis is an inflammation of the brain parenchyma that leads to neurological dysfunction and is most commonly caused by infections. These infections may be viral, bacterial, fungal, or protozoal, with viruses being the most frequent cause. The condition typically arises when pathogens spread to the central nervous system via the bloodstream, although some, such as rabies, travel through peripheral nerves. Clinically, encephalitis often presents with fever, headache, confusion, and altered mental status, and may also involve seizures or focal neurological deficits.
Epidemiologically, encephalitis affects both extremes of age, particularly the very young and the elderly. Viral encephalitis is the most common form, with an annual incidence of approximately 3.5–7.4 cases per 100,000 people, accounting for around 20,000 new cases each year. In the United States, herpes simplex virus (HSV) is the leading identifiable cause, responsible for about 10% of all cases. In neonates, HSV-2 is the most common cause and is typically acquired during delivery. In many cases—up to 75%—no specific causative agent is identified.
Risk factors for encephalitis include age, immune status, seasonal exposure, and environmental or travel-related exposures. Arboviral infections are more common during summer and fall, while HSV infections occur year-round. Exposure to mosquitoes, ticks, animals, or contaminated water sources increases risk. Preventive strategies include avoiding insect bites, implementing vector control measures, and vaccination against preventable viral causes such as measles, mumps, rubella, polio, varicella, and Japanese encephalitis.
The pathophysiology varies depending on the causative organism but generally involves viremia followed by invasion of the central nervous system. This leads to inflammation, neuronal injury, and sometimes necrosis. In HSV encephalitis, the temporal lobes are commonly affected, whereas other viruses may target different brain regions such as the brainstem or gray matter.
Etiologically, encephalitis has a broad range of causes. Viral pathogens include herpesviruses (HSV, CMV, VZV), arboviruses (e.g., West Nile virus, Japanese encephalitis virus), enteroviruses, rabies virus, and HIV. Bacterial causes include Listeria monocytogenes, Mycobacterium tuberculosis, and Mycoplasma. Other causes include rickettsial organisms, spirochetes such as Borrelia burgdorferi, fungi like Cryptococcus neoformans, and protozoa such as Toxoplasma gondii and Naegleria fowleri. Helminths such as Taenia solium may also be implicated.
Diagnosis relies heavily on clinical suspicion, supported by history and examination. Important historical clues include recent travel, insect or animal exposure, and immune status. Physical examination focuses on neurological findings, though skin examination may reveal rashes that help identify specific etiologies. Because encephalitis may overlap clinically with meningitis, distinguishing between the two can be challenging.
Laboratory evaluation includes cerebrospinal fluid (CSF) analysis obtained via lumbar puncture, which typically shows lymphocytic pleocytosis, elevated protein, and normal glucose in viral cases. PCR testing of CSF is essential for identifying viral pathogens such as HSV, CMV, and VZV. Additional tests may include serology, blood cultures, and pathogen-specific assays depending on clinical suspicion. Imaging is critical, with brain MRI being the gold standard; characteristic findings such as temporal lobe involvement suggest HSV encephalitis. CT scanning is useful when MRI is unavailable or to rule out contraindications to lumbar puncture.
The differential diagnosis is broad and includes meningitis, brain abscess, encephalopathy, acute disseminated encephalomyelitis, metabolic disorders, vasculitis, and drug-induced aseptic meningitis. Management requires prompt empiric therapy. Until bacterial meningitis is excluded, patients should receive broad antimicrobial coverage along with antiviral therapy. Intravenous acyclovir is the treatment of choice for suspected HSV encephalitis and should be started immediately. Other antiviral or antimicrobial treatments depend on the identified pathogen, and adjunctive therapies such as antiretroviral treatment may be required in HIV-related cases.
Patients with encephalitis require hospitalization, often with intensive care monitoring. Supportive care includes adequate hydration, especially during acyclovir therapy to prevent renal toxicity. Close monitoring is essential, as recovery may be prolonged and incomplete.
The prognosis of encephalitis varies widely depending on the causative organism and timeliness of treatment. HSV encephalitis, if untreated, carries a mortality rate of up to 70%, but early treatment reduces mortality to 6–19%. However, many survivors experience long-term neurological deficits. Younger patients tend to have better outcomes.
Complications of encephalitis include seizures, permanent neurological impairment, relapse (particularly in HSV infection), and death. Long-term follow-up may involve neuropsychological assessment to evaluate cognitive and functional outcomes.
Encephalitis is an inflammation of the brain parenchyma that leads to neurological dysfunction and is most commonly caused by infections. These infections may be viral, bacterial, fungal, or protozoal, with viruses being the most frequent cause. The condition typically arises when pathogens spread to the central nervous system via the bloodstream, although some, such as rabies, travel through peripheral nerves. Clinically, encephalitis often presents with fever, headache, confusion, and altered mental status, and may also involve seizures or focal neurological deficits.
Epidemiologically, encephalitis affects both extremes of age, particularly the very young and the elderly. Viral encephalitis is the most common form, with an annual incidence of approximately 3.5–7.4 cases per 100,000 people, accounting for around 20,000 new cases each year. In the United States, herpes simplex virus (HSV) is the leading identifiable cause, responsible for about 10% of all cases. In neonates, HSV-2 is the most common cause and is typically acquired during delivery. In many cases—up to 75%—no specific causative agent is identified.
Risk factors for encephalitis include age, immune status, seasonal exposure, and environmental or travel-related exposures. Arboviral infections are more common during summer and fall, while HSV infections occur year-round. Exposure to mosquitoes, ticks, animals, or contaminated water sources increases risk. Preventive strategies include avoiding insect bites, implementing vector control measures, and vaccination against preventable viral causes such as measles, mumps, rubella, polio, varicella, and Japanese encephalitis.
The pathophysiology varies depending on the causative organism but generally involves viremia followed by invasion of the central nervous system. This leads to inflammation, neuronal injury, and sometimes necrosis. In HSV encephalitis, the temporal lobes are commonly affected, whereas other viruses may target different brain regions such as the brainstem or gray matter.
Etiologically, encephalitis has a broad range of causes. Viral pathogens include herpesviruses (HSV, CMV, VZV), arboviruses (e.g., West Nile virus, Japanese encephalitis virus), enteroviruses, rabies virus, and HIV. Bacterial causes include Listeria monocytogenes, Mycobacterium tuberculosis, and Mycoplasma. Other causes include rickettsial organisms, spirochetes such as Borrelia burgdorferi, fungi like Cryptococcus neoformans, and protozoa such as Toxoplasma gondii and Naegleria fowleri. Helminths such as Taenia solium may also be implicated.
Diagnosis relies heavily on clinical suspicion, supported by history and examination. Important historical clues include recent travel, insect or animal exposure, and immune status. Physical examination focuses on neurological findings, though skin examination may reveal rashes that help identify specific etiologies. Because encephalitis may overlap clinically with meningitis, distinguishing between the two can be challenging.
Laboratory evaluation includes cerebrospinal fluid (CSF) analysis obtained via lumbar puncture, which typically shows lymphocytic pleocytosis, elevated protein, and normal glucose in viral cases. PCR testing of CSF is essential for identifying viral pathogens such as HSV, CMV, and VZV. Additional tests may include serology, blood cultures, and pathogen-specific assays depending on clinical suspicion. Imaging is critical, with brain MRI being the gold standard; characteristic findings such as temporal lobe involvement suggest HSV encephalitis. CT scanning is useful when MRI is unavailable or to rule out contraindications to lumbar puncture.
The differential diagnosis is broad and includes meningitis, brain abscess, encephalopathy, acute disseminated encephalomyelitis, metabolic disorders, vasculitis, and drug-induced aseptic meningitis. Management requires prompt empiric therapy. Until bacterial meningitis is excluded, patients should receive broad antimicrobial coverage along with antiviral therapy. Intravenous acyclovir is the treatment of choice for suspected HSV encephalitis and should be started immediately. Other antiviral or antimicrobial treatments depend on the identified pathogen, and adjunctive therapies such as antiretroviral treatment may be required in HIV-related cases.
Patients with encephalitis require hospitalization, often with intensive care monitoring. Supportive care includes adequate hydration, especially during acyclovir therapy to prevent renal toxicity. Close monitoring is essential, as recovery may be prolonged and incomplete.
The prognosis of encephalitis varies widely depending on the causative organism and timeliness of treatment. HSV encephalitis, if untreated, carries a mortality rate of up to 70%, but early treatment reduces mortality to 6–19%. However, many survivors experience long-term neurological deficits. Younger patients tend to have better outcomes.
Complications of encephalitis include seizures, permanent neurological impairment, relapse (particularly in HSV infection), and death. Long-term follow-up may involve neuropsychological assessment to evaluate cognitive and functional outcomes.
- Published on
Infectious Disease And Microbiology – Empyema
Empyema is defined as the accumulation of purulent (pus-containing) fluid within the pleural cavity. It most commonly develops as a complication of bacterial pneumonia but may also arise following thoracic surgery, trauma, esophageal perforation, or subdiaphragmatic infections. In children, empyema is usually secondary to pneumonia—most often caused by Streptococcus pneumoniae—and tends to have a better prognosis than in adults, although management principles are similar. Overall, pleural effusions occur in up to 57% of pneumonia cases, but only about 1–2% progress to empyema. The condition affects individuals of all ages, with higher prevalence in the elderly and in children, and occurs more frequently in males.
Several risk factors predispose individuals to empyema, including diabetes mellitus, alcoholism, substance abuse, rheumatoid arthritis, chronic lung disease, poor dental hygiene, malignancy, and prior thoracic surgery. Conditions that increase the risk of aspiration are particularly associated with anaerobic infections. Prevention focuses on appropriate treatment of pneumonia, adherence to surgical infection control practices, and vaccination (especially pneumococcal vaccination).
The development of empyema progresses through three stages. The exudative stage involves inflammation and fluid accumulation in the pleural space. This is followed by the fibrinopurulent stage, characterized by fibrin deposition and pus formation. Finally, the organizing stage occurs, where fibroblasts proliferate and collagen is deposited, potentially leading to pleural thickening and restricted lung expansion. The causative organisms vary depending on whether the infection is community-acquired or hospital-acquired. Community-acquired empyema commonly involves streptococci, staphylococci, anaerobes, and Enterobacteriaceae, while hospital-acquired cases are more often caused by methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, enterococci, and other resistant organisms.
Clinically, patients often present with a history of pneumonia or thoracic procedures, along with symptoms such as fever, chest pain, and shortness of breath. In elderly or immunocompromised patients, symptoms may be subtle, including weight loss or anemia. On physical examination, findings may include dullness to percussion, decreased tactile fremitus, and absent breath sounds over the affected area, although small effusions may not produce obvious signs.
Diagnosis is confirmed through thoracentesis, with the presence of pus in the pleural space being definitive. Laboratory evaluation includes complete blood count and inflammatory markers such as C-reactive protein. Pleural fluid analysis is essential and typically shows low pH (<7.2), high white blood cell count, and positive Gram stain or culture. Imaging plays a key role: chest X-ray identifies pleural effusion, ultrasound helps localize fluid and guide drainage, and CT scan can distinguish empyema from lung abscess (notably showing the “split pleura” sign).
The differential diagnosis includes other causes of pleural effusion, lung abscess, and pneumonia. Management requires prompt initiation of antimicrobial therapy along with drainage of the infected fluid, usually via chest tube. Antibiotic regimens differ based on whether the infection is community- or hospital-acquired and should cover likely pathogens, including anaerobes and resistant organisms where appropriate. Adjunctive treatments include adequate hydration, nutritional support, and, in some cases, intrapleural fibrinolytic therapy to improve drainage.
In cases where drainage is incomplete or complications arise, surgical intervention may be necessary. Options include video-assisted thoracoscopic surgery (VATS), thoracotomy with decortication, or other open surgical procedures. Most patients require hospitalization for intravenous antibiotics and monitoring. Follow-up involves continued antibiotic therapy for 2–4 weeks, monitoring inflammatory markers, and ensuring adequate drainage. Chest tubes are typically removed once drainage decreases and fluid clears.
The prognosis of empyema varies depending on patient factors and timeliness of treatment. While many patients recover with appropriate management, mortality rates range from 7% to 33% within one year and may exceed 50% in patients with significant comorbidities. Complications include pleural thickening, pulmonary fibrosis, pneumothorax, bronchopleural fistula, respiratory failure, septic shock, and, in rare cases, empyema necessitatis.
- Published on
Infectious Disease and Microbiology – E. coli Infections
Escherichia coli are Gram-negative, rod-shaped bacteria that are part of the normal intestinal flora but can also cause a wide range of infections. They are among the most important pathogens in both community-acquired and hospital-acquired infections.
Epidemiologically, E. coli is the leading cause of nosocomial bacteremia and is responsible for more than 80% of acute uncomplicated urinary tract infections in young women. It is also a major cause of traveler’s diarrhea, typically acquired via the fecal–oral route through contaminated food or water, especially in tropical and subtropical regions. Urinary tract infections often occur due to colonization of the periurethral area followed by ascending infection. Risk factors in women include sexual activity and use of spermicides or diaphragms. In men, risks include lack of circumcision, anal intercourse, and exposure to colonized partners. Immunocompromised individuals, including those with HIV (especially CD4 <200), are also at increased risk.
Additional risk factors include anatomical abnormalities such as urinary obstruction or stones, immunosuppression (e.g., diabetes, malignancy, steroid use), and certain host susceptibility factors such as inability to secrete blood group antigens, which facilitates bacterial adherence. Preventive strategies include careful use of antibiotic prophylaxis in selected travelers and avoiding unnecessary screening for asymptomatic bacteriuria except in specific groups such as pregnant women.
The pathophysiology of E. coli infections is based on its ability to adhere to host cells and produce toxins. Different strains have distinct pathogenic mechanisms. Enterotoxigenic E. coli (ETEC) produces toxins that increase cyclic nucleotide levels, leading to increased chloride secretion and watery diarrhea. Enteropathogenic strains disrupt intestinal mucosa, especially in children. Enteroinvasive strains invade intestinal cells, causing inflammatory diarrhea. Enterohemorrhagic E. coli (EHEC), such as O157:H7, produces Shiga toxin and can cause hemorrhagic colitis and hemolytic–uremic syndrome, often associated with contaminated beef or dairy products. Enteroaggregative strains are linked to persistent diarrhea, particularly in travelers and immunocompromised patients.
Uropathogenic E. coli strains possess specific virulence factors, including pili that allow adherence to uroepithelial cells, leading to infections ranging from cystitis to pyelonephritis and even septicemia. Beyond the urinary and gastrointestinal systems, E. coli can cause intra-abdominal infections such as abscesses, cholecystitis, and cholangitis. It is also associated with serious conditions including meningitis in neonates, as well as endocarditis, pneumonia, osteomyelitis, septic arthritis, and other systemic infections.
Diagnosis is confirmed by isolating E. coli from normally sterile sites such as blood, cerebrospinal fluid, or bile. In diarrheal illness, specialized testing such as PCR or toxin detection may be required to identify specific pathogenic strains. Imaging studies like abdominal CT or ultrasound may help identify complications such as abscesses or hepatobiliary infections. The differential diagnosis depends on the clinical presentation and includes other bacterial causes such as Campylobacter, Salmonella, and Shigella, particularly in cases of bloody diarrhea.
Treatment depends on the type and severity of infection. Localized infections require both antimicrobial therapy and, when necessary, drainage of abscesses or removal of infected material. Traveler’s diarrhea is commonly treated with short courses of fluoroquinolones or trimethoprim–sulfamethoxazole, along with supportive therapy such as hydration and antidiarrheal agents. However, antibiotics are generally avoided in EHEC infections due to the risk of worsening toxin-mediated complications such as hemolytic–uremic syndrome.
Uncomplicated cystitis is treated with short courses of oral antibiotics, while pyelonephritis requires longer treatment and sometimes hospitalization for intravenous therapy. Severe infections such as bacteremia or sepsis require broad-spectrum intravenous antibiotics, including fluoroquinolones, third-generation cephalosporins, or carbapenems. Pregnant patients require specific antibiotic choices such as penicillins, cephalosporins, or nitrofurantoin.
Follow-up is important in patients with persistent bacteremia or recurrent infections, as these may indicate underlying abnormalities such as abscesses, urinary tract obstruction, or foreign bodies. Prognosis is generally good with appropriate treatment, although complications such as dehydration, septic shock, and hemolytic–uremic syndrome can occur. Severe systemic infections may be life-threatening, particularly in vulnerable populations such as those with liver disease, immunosuppression, or impaired immune function.
